T-PA Approved in South Korea

South San Francisco, Calif. -- August 31, 1987 -- Genentech, Inc. announced today that its foreign licensee, Boehringer Ingelheim International GmbH, has received approval to market tissue plasminogen activator (t-PA) in South Korea for the treatment of heart attack patients. The company added that Boehringer Ingelheim begins marketing t-PA in Austria on September 1.

T-PA, which will be marketed outside of North America under the trademark Actilyse®, is a human protein that dissolves blood clots that cause heart attacks. It has been tested in over 5,000 patients worldwide in clinical trials since early 1984.

Actilyse® has now been approved in five countries including Austria,

France, New Zealand and the Philippines. Genentech will receive royalties on product sales outside of the U.S. and Canada.

Genentech is a leading biotechnology company, focusing on the development, manufacture and marketing of pharmaceuticals produced by recombinant DNA technology.

# # #